Company

CEO Company

HysensBio History

  • icon1
    lineicon

    • 1999

    • · Began scientific research on dentin regeneration
  • icon2
    lineicon

    • 2016

    • · Confirmed regenerative function of dentin regenerative protein
    • · Established HysensBio Co., Ltd.
  • icon3
    lineicon

    • 2017

    • · Established Corporate R&D Center
    • · Developed the novel KH001 functional peptide
    • · Funded by Korean Ministry of Commerce Industry & Energy (KRW 2B)
  • icon4
    lineicon

    • 2018

    • · Funded by Korea Investment Partners: Series A (KRW 2B)
    • · Registered patent related to dentin regeneration
  • icon5 icon6
    lineicon

    • 2019

    • · Funded by Korea Investment Partners, DAYLI Partners, Timefolio Asset Management: Series B (KRW 7B)
    • · New Technology Award, Ministry of Commerce Industry & Energy (Nov 2019)
  • icon7 icon8
    lineicon

    • 2020

    • · Grand prize in Creative Innovation of 50+ Awards, LINA Korea
    • · Selected as Potential Unicorn Corporate by Ministry of SMEs & Startups
    • · Applied patent related to periodontium regeneration
    • · Approved of IND for clinical trials
  • icon9
    lineicon

    • 2021

    • · Certified as a small and medium-sized business for talent development by the Ministry of SMEs and Startups
    • · Series C 투자: 13 billion won
    • · Received the Korea Health Industry Promotion Agency President’s Award for commercialization of health and medical technology
    • · Certified as a family-friendly company by the Ministry of Gender Equality and Family
  • icon10
    lineicon

    • 2022

    • · KH001 clinical trial phase 1 completed, 2a progress